Management of Tardive Dyskinesia

The first description of tardive dyskinesia (TD) was in 1957, following the introduction of the first antipsychotic therapies, and while TD was mainly linked to first-generation antipsychotics, TD can also be associated with second-generation antipsychotics, but with a lower risk. Professor at the Center for Psychiatric Neuroscience at the Feinstein Institute for Medical Research and medical director of the Recognition and Prevention Program in the Department of Psychiatry at the Zucker Hillside Hospital in Manhasset, New York, Christoph Correll, MD, says that TD is underassessed, as there is little training and experience with TD in the current generation of psychiatrists. The initial onset of TD also presents with inconsistent symptoms that can be confused with symptoms of medication-induced adverse effects or other disorders, he explained. TD is usually diagnosed using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and the Schooler-Kane criteria. Over the past few years, evidence-based guidelines have been developed for the treatment of TD.

Reference: Yasgur BS. Old Challenges and New Directions in Managing Tardive Dyskinesia. Published March 30, 2018. Accessed July 14, 2022.

Related Articles